Zeposia FDA Approval History
Last updated by Judith Stewart, BPharm on June 1, 2021.
FDA Approved: Yes (First approved March 25, 2020)
Brand name: Zeposia
Generic name: ozanimod
Dosage form: Capsules
Company: Bristol-Myers Squibb Company
Treatment for: Multiple Sclerosis, Ulcerative Colitis
Zeposia (ozanimod) is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults; and moderately to severely active ulcerative colitis (UC) in adults.
Development Timeline for Zeposia
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.